Exploitation of protein kinase C: A useful target for cancer therapy

• Published in: Cancer treatment reviews Vol. 35; no. 1; pp. 1 - 8
• Main Authors: Ali, Ashhar S, Ali, Shadan, El-Rayes, Bassel F, Philip, Philip A, Sarkar, Fazlul H
• Format: Journal Article
• Language: English
• Published: Netherlands Elsevier Ltd 01.02.2009
• Subjects: Gene Expression Regulation, Enzymologic - physiology; Hematology, Oncology and Palliative Medicine; Humans; Invasion; Metastasis; Neoplasms - genetics; Neoplasms - therapy; PKC isoenzymes; Protein Kinase C - antagonists & inhibitors; Protein Kinase C - genetics; PKC isoenzymes; Invasion; Metastasis
• ISSN: 0305-7372; 1532-1967
• DOI: 10.1016/j.ctrv.2008.07.006

Summary Protein kinase C is a family of serine/threonine kinases. The PKC family is made up of at least 12 isozymes, which have a role in cell proliferation, differentiation, angiogenesis, and apoptosis. Activation of PKC isozyme is dependent on tyrosine-kinase receptors and G-protein-coupled receptors. PKC isozymes regulate multiple signaling pathways including PI3-K/Akt, MAPK, and GSK-3β. PKC isozymes have variable roles in tumor biology which in part depend on the cell type and intracellular localization. PKC isozymes are commonly dysregulated in the cancer of the prostate, breast, colon, pancreatic, liver, and kidney. Currently, several classes of PKC inhibitors are being evaluated in clinical trials and several challenges in targeting PKC isozymes have been recently identified. In conclusion, PKC remains a promising target for cancer prevention and therapy.